Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm

Summary

The primary objective of this study is to demonstrate the superiority of at least 1 dose of intranasal (IN) MSP-2017 (Etripamil) over placebo in terminating PSVT induced in an electrophysiology (EP) laboratory.

Timeline

Start

2015-03-27

Primary completion

2016-12

Completion

2016-12

Outcome

Met primary endpoint

paper Conversion rates from SVT to sinus rhythm were between 65% and 95% in the etripamil nasal spray groups and 35% in the placebo group PMID 30049309 ↗

paper the differences were statistically significant (Pearson chi-square test) in the 3 highest active compound dose groups versus placebo. PMID 30049309 ↗

Publications

• Stambler BS, Dorian P, Sager PT, Wight D, Douville P, Potvin D, Shamszad P, Haberman RJ, Kuk RS, Lakkireddy DR, Teixeira JM, Bilchick KC, Damle RS, Bernstein RC, Lam WW, O'Neill G, Noseworthy PA, Venkatachalam KL, Coutu B, Mondesert B, Plat F. Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. J Am Coll Cardiol. 2018 Jul 31;72(5):489-497. doi: 10.1016/j.jacc.2018.04.082.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Etripamil	Small molecule	35 mg	Intranasal
Subject	Etripamil	Small molecule	70 mg	Intranasal
Subject	Etripamil	Small molecule	105 mg	Intranasal
Subject	Etripamil	Small molecule	140 mg	Intranasal

Indications